BioNTX Names Osteal Therapeutics 2023 Rising Star
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award...
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award...
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining...
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be...
Cannabis industry veteran brings over a decade of experience in retail operations, leadership and business analysisSAN DIEGO and TORONTO, Sept....
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a...
Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based...
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in...
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe...
CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing...
Proposed capital increase with preferential subscription rights, to be carried out in January 2024 to strengthen IMPLANET’s equity capital and...
FendX Technologies Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation...
Revenue of €4.3 million in the first half of 2023, +4% compared with H1 2022 Continued dynamic R&D investment coupled...
LONDON, UK / ACCESSWIRE / September 28, 2023 / Genflow (LSE:GENF) is pleased to announce its half year results for...
HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress...